Navellier & Associates Inc Enanta Pharmaceuticals Inc Transaction History

Navellier & Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$46.37 - $57.58 $292,131 - $362,754	-6,300 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$57.95 - $66.61 $43,114 - $49,557	-744 Reduced 10.56%	6,300 $389,000
Q3 2019 Oct 16, 2019	SELL	$60.08 - $88.17 $157,589 - $231,269	-2,623 Reduced 27.13%	7,044 $423,000
Q2 2019 Jul 17, 2019	SELL	$81.3 - $97.35 $78,861 - $94,429	-970 Reduced 9.12%	9,667 $816,000
Q1 2019 May 15, 2019	SELL	$69.08 - $105.66 $1.31 Million - $2 Million	-18,957 Reduced 64.06%	10,637 $1.02 Million
Q4 2018 Jan 15, 2019	BUY	$65.41 - $84.65 $209,377 - $270,964	3,201 Added 12.13%	29,594 $2.1 Million
Q3 2018 Nov 14, 2018	BUY	$85.46 - $126.37 $642,146 - $949,544	7,514 Added 39.8%	26,393 $2.26 Million
Q2 2018 Aug 06, 2018	BUY	$81.85 - $120.51 $755,229 - $1.11 Million	9,227 Added 95.6%	18,879 $2.19 Million
Q1 2018 May 21, 2018	BUY	$57.91 - $92.15 $558,947 - $889,431	9,652 New	9,652 $781,000

21.2M

10.4K

2.3K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $215M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.